Schott A, Simon T, Muller S, Rausch A, Busch B, Glass M
NAR Cancer. 2025; 7(1):zcaf006.
PMID: 40008228
PMC: 11850222.
DOI: 10.1093/narcan/zcaf006.
Vaicekauskaite I, Kazlauskaite P, Gineikaite R, ciurliene R, Lazutka J, Sabaliauskaite R
Biomedicines. 2025; 13(2).
PMID: 40002854
PMC: 11853219.
DOI: 10.3390/biomedicines13020441.
Harada H, Hachisuga T, Harada Y, Shibahara M, Murakami M, Nuratdinova F
Diagnostics (Basel). 2025; 15(4).
PMID: 40002574
PMC: 11854212.
DOI: 10.3390/diagnostics15040422.
Erdemoglu E, Langstraat C, Kumar A, Ostby S, Girardo M, Giannini A
Cancers (Basel). 2025; 17(3).
PMID: 39941778
PMC: 11815761.
DOI: 10.3390/cancers17030410.
Abdul-Aziz S, Bhattarai N, Vale L, Sagoo G, Mukhopadhyay A
Gynecol Oncol Rep. 2025; 57:101680.
PMID: 39917724
PMC: 11800098.
DOI: 10.1016/j.gore.2025.101680.
Textbook outcome in ovarian cancer and its impact on survival: comparative study.
Carbonell-Morote S, Arjona-Sanchez A, Cascales-Campos P, Gonzalez-Gil A, Gomez-Duenas G, Gil-Gomez E
World J Surg Oncol. 2025; 23(1):32.
PMID: 39893428
PMC: 11786506.
DOI: 10.1186/s12957-025-03686-5.
The emergence of DNAM-1 as the facilitator of NK cell-mediated killing in ovarian cancer.
Pounds R, Croft W, Pearce H, Hossain T, Singh K, Balega J
Front Immunol. 2025; 15():1477781.
PMID: 39835114
PMC: 11743932.
DOI: 10.3389/fimmu.2024.1477781.
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence.
Loverro M, Marchetti C, Salutari V, Giannarelli D, Vertechy L, Capomacchia F
ESMO Open. 2025; 10(2):104119.
PMID: 39826478
PMC: 11786059.
DOI: 10.1016/j.esmoop.2024.104119.
Ovarian cancer staging and follow-up: updated guidelines from the European Society of Urogenital Radiology female pelvic imaging working group.
Rizzo S, Avesani G, Panico C, Manganaro L, Gui B, Lakhman Y
Eur Radiol. 2025; .
PMID: 39798005
DOI: 10.1007/s00330-024-11300-7.
Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review.
Gonzalez A, Kistenfeger Q, Cosgrove C
Int J Womens Health. 2024; 16:2239-2246.
PMID: 39720673
PMC: 11668310.
DOI: 10.2147/IJWH.S466250.
Actionable mutations in early-stage ovarian cancer according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): a descriptive analysis on a large prospective cohort.
Camarda F, Mastrantoni L, Parrillo C, Minucci A, Persiani F, Giannarelli D
ESMO Open. 2024; 10(1):104090.
PMID: 39705839
PMC: 11730936.
DOI: 10.1016/j.esmoop.2024.104090.
Anatomy, Imaging, and Surgical Treatment of Thoracic Lymphadenopathies in Advanced Epithelial Ovarian Cancer.
Rizzo S, Gasparri M, Manganaro L, Del Grande F, Papadia A, Petrella F
Cancers (Basel). 2024; 16(23).
PMID: 39682172
PMC: 11640282.
DOI: 10.3390/cancers16233985.
Δ-Peritoneal Cancer Index (Δ-PCI) to Predict Complete Cytoreduction and Histopathological Response to Neoadjuvant Chemotherapy in Ovarian Cancer.
Spagnol G, Bigardi S, Zorzi M, Morotti M, Carollo M, Bruni G
J Clin Med. 2024; 13(22).
PMID: 39598059
PMC: 11595135.
DOI: 10.3390/jcm13226915.
Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility study.
Pandraklakis A, Liakou C, La Russa M, Ochoa-Ferraro R, Stearns A, Burbos N
Gynecol Oncol Rep. 2024; 56:101536.
PMID: 39524471
PMC: 11550337.
DOI: 10.1016/j.gore.2024.101536.
The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study.
Presl J, Havelka P, Weinberger V, Ovesna P, Fekete P, Fruhauf F
Cancers (Basel). 2024; 16(21).
PMID: 39518007
PMC: 11544767.
DOI: 10.3390/cancers16213566.
The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer.
Tonti N, Golia DAuge T, Cuccu I, De Angelis E, DOria O, Perniola G
Int J Mol Sci. 2024; 25(20).
PMID: 39457020
PMC: 11508316.
DOI: 10.3390/ijms252011239.
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis.
Zhou Y, Xu J
World J Surg Oncol. 2024; 22(1):276.
PMID: 39434111
PMC: 11492665.
DOI: 10.1186/s12957-024-03562-8.
The Predictive Value of the Fibrinogen-Albumin-Ratio Index on Surgical Outcomes in Patients with Advanced High-Grade Serous Ovarian Cancer.
Postl M, Danisch M, Schrott F, Kofler P, Petrov P, Aust S
Cancers (Basel). 2024; 16(19).
PMID: 39409916
PMC: 11476045.
DOI: 10.3390/cancers16193295.
Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?.
Onoprienko A, Bartl T, Grimm C, Concin N, Polterauer S
Cancers (Basel). 2024; 16(19).
PMID: 39409889
PMC: 11476324.
DOI: 10.3390/cancers16193268.
Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma.
Zwimpfer T, Ewald H, Bilir E, Jayawardana M, Appenzeller-Herzog C, Bizzarri N
Cochrane Database Syst Rev. 2024; 9:CD015896.
PMID: 39312297
PMC: 11418971.
DOI: 10.1002/14651858.CD015896.